Corvus Pharmaceuticals (NASDAQ: CRVS) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Institutional and Insider Ownership
84.8% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 8.8% of Brainstorm Cell Therapeutics shares are held by institutional investors. 46.4% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 24.7% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Corvus Pharmaceuticals and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-76.45%||-59.84%|
Valuation & Earnings
This table compares Corvus Pharmaceuticals and Brainstorm Cell Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corvus Pharmaceuticals||N/A||N/A||-$36.37 million||($2.69)||-3.00|
|Brainstorm Cell Therapeutics||N/A||N/A||-$4.98 million||($0.32)||-9.69|
Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings for Corvus Pharmaceuticals and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||1||0||3.00|
Corvus Pharmaceuticals currently has a consensus target price of $21.67, indicating a potential upside of 168.82%. Brainstorm Cell Therapeutics has a consensus target price of $9.00, indicating a potential upside of 190.32%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Corvus Pharmaceuticals.
Volatility and Risk
Corvus Pharmaceuticals has a beta of -2.39, meaning that its stock price is 339% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Corvus Pharmaceuticals beats Brainstorm Cell Therapeutics on 6 of the 11 factors compared between the two stocks.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.